Jane Street
LXRX icon

Jane Street’s Lexicon Pharmaceuticals LXRX Stock Holding History

Jane Street’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,500
Closed -$22.6K – 12480
2026
Q1 		$22.6K Buy
+14,500
New +$21.1K ﹤0.01% 11174
2025
Q4 		– Sell
-11,300
Closed -$15.3K – 11862
2025
Q3 		$15.3K Buy
+11,300
New +$12.8K ﹤0.01% 10560
2024
Q3 		– Sell
-19,100
Closed -$32.1K – 10077
2024
Q2 		$32.1K Hold
19,100
– – ﹤0.01% 8995
2024
Q1 		$45.8K Buy
+19,100
New +$41K ﹤0.01% 8755
2023
Q3 		– Sell
-76,000
Closed -$174K – 9064
2023
Q2 		$174K Buy
+76,000
New +$202K ﹤0.01% 7738
2021
Q3 		– Sell
-20,700
Closed -$95K – 10392
2021
Q2 		$95K Buy
+20,700
New +$99.7K ﹤0.01% 9288

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jane Street's LXRX Position: Q2 2026 in Review

Jane Street sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 2,665,938 shares — an estimated $5.19M sold.

Jane Street first reported a position in LXRX in Q3 2013 and held it in 25 quarters. The position peaked at $4.16M in Q1 2026. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Jane Street reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 2,665,938 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $5.19M.
  • Jane Street first reported a position in Lexicon Pharmaceuticals in Q3 2013 and held it in 25 quarters.
  • Jane Street's Lexicon Pharmaceuticals position peaked at $4.16M in Q1 2026.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.